Is the GSK share price good value after the 13% fall last week?

Jon Smith considers the reason behind the sharp fall in the GSK share price last week, and wonders if now is the time for him to buy the stock.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Risk reward ratio / risk management concept

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The worst-performing FTSE 100 stock last week was GSK (LSE:GSK). It dropped by almost 13%, in a week when the top gainer rose by 23%. There were some fundamental drivers behind the slump in the GSK share price, which have changed my view on whether I want to invest right now. Here are the details.

FDA action

Last week, it emerged that GSK is now involved in around 3,000 personal injury claims, relating to Zantac. Even as I write, I can understand the incredible headache that this is going to cause going forward. The amount of press stories, expensive legal fees and distraction from GSK’s other business lines are all likely. The major cases are due to begin in early 2023.

The fall in the share price last week was linked to the concern investors have about lawsuits in the US. The US Food and Drug Administration (FDA) forced GSK to pull a drug named Zantac from shelves back in 2019. The worry was that it was claimed some components within the drug contributed towards cancer.

We’ll have to see how these cases pan out and what precedent is set in early court sessions. It’s too early for me to make a judgement call on the future share price based on current information. However, the drop last week as news on this topic broke is a clear sign that some investors aren’t keen to wait and see what happens.

Taking a step back

Putting this issue to one side, over the past year GSK shares are only down by 4%. Financial performance during this period has been solid.

Q2 results from last month highlighted turnover growth of 19% year on year, with the outlook for the rest of 2022 promising. The company stated that it expects full-year “sales to increase between 6-8% and adjusted operating profit to increase between 13-15%”.

The company is also lighter after having spun-off some brands in a new listed entity, Haleon. Although this reduces the size of GSK, there are plenty of good arguments supporting the move on the grounds of higher efficiency and being more nimble.

Is the GSK share price good value?

Including the slump last week, I estimate the price-to-earnings ratio to be 16.55. By comparison, industry peers’ P/E ratios are 11.46 (Hikma Pharmaceuticals), and 69.51 (Dechra Pharmaceuticals). So I’d conclude that the current price seems fair value.

The share price would need to rally 26% before reaching the one-year highs, and fall around 6% before reaching the lows. So from a technical perspective, the share price does look appealing.

The concern I have is that I don’t think the full impact of the lawsuits has been felt yet. This could blow up into a large-scale issue, or simply be headline noise that quickly fades. I don’t think we’ll know the answer for some time, but this uncertainty makes me cautious about investing.

Ultimately, I think the GSK share price is at a fair value, rather than a great value. I’m happy to sit on the sideline for the moment, with the aim of buying when more clarity on the lawsuits comes through.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jon Smith has no position in any of the shares mentioned. The Motley Fool UK has recommended GSK plc, Haleon plc, and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Shot of a young Black woman doing some paperwork in a modern office
Investing Articles

With an 8% dividend yield, I think this undervalued FTSE stock is a no-brainer buy

With an impressive yield and good track record of payments, Mark David Hartley is considering adding this promising FTSE share…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£9,500 in savings? Here’s how I’d try to turn that into £1,809 a month of passive income

Investing a relatively small amount into high-yielding stocks and reinvesting the dividends paid can generate significant passive income over time.

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

Dividend star Legal & General’s share price is still marked down, so should I buy more?

Legal & General’s share price looks very undervalued against its peers. But it pays an 8%+ dividend yield, and has…

Read more »

Investing Articles

Dividend shares: 1 FTSE 100 stock to consider buying for chunky shareholder income

This company’s ‘clean’ dividend record looks attractive to me and I’d consider buying some of the shares to hold long…

Read more »

Investing Articles

3 of my top FTSE 250 stocks to consider buying before April

Buying undervalued UK shares can be a great way to generate long-term wealth. Here, Royston Wild reveals a handful on…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »